HeartWare CEO details Q4, 2012 preliminary results

January 7, 2013 by MassDevice staff

HeartWare International CEO Doug Godshall reveals the medical device company's preliminary sales figures for the 4th quarter and 2012, saying the company expects to get 100 commercial sites online in the U.S. this year.

HeartWare International

HeartWare International (NSDQ:HTWR) posted strong double-digit sales growth during both the 4th quarter and 2012, CEO Doug Godshall told investors today at the J.P. Morgan healthcare conference in San Francisco.

Framingham, Mass.-based HeartWare, which makes implantable heart pumps, logged about $32 million in revenues for the 3 months ended Dec. 31, Godshall said, and recorded 2012 sales of about $110 million, for growth of about 40% and 33%, respectively, compared with the prior-year periods.

HeartWare expects to have 100 implantation centers up and running in the U.S. by the end of 2013, he said. Forty of 50 clinical sites have shifted from clinical to commercial status since the company won premarket approval for its flagship implantable left ventricular assist device last November, Godshall noted.

Sign up to get our free newsletters delivered straight to your inbox

"We finally have a chance to hunt in the biggest market," Godshall said.

In terms of product pipeline, HeartWare expects to land an FDA nod for its next-generation MVAD device this year; its Longhorn device in 2014; and a device aimed at the NYHA Class III patient population in 2016 or thereafter, he said.